Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Subtype terms (14)
More specific conditions that are subtypes of Drug-Related Side Effects and Adverse Reactions in the MeSH hierarchy.
- Akathisia, Drug-Induced
3 drugs (2 approved, 1 experimental)
- Anticholinergic Syndrome
1 drug approved
- Cardiotoxicity
72 drugs (62 approved, 10 experimental)
- Chemical and Drug Induced Liver Injury
44 drugs (34 approved, 10 experimental)
- Chemotherapy-Related Cognitive Impairment
6 drugs (2 approved, 4 experimental)
- Drug Hypersensitivity
6 drugs (5 approved, 1 experimental)
- Dyskinesia, Drug-Induced
13 drugs (8 approved, 5 experimental)
- Injection Site Reaction
9 drugs (7 approved, 2 experimental)
- Metabolic Side Effects of Drugs and Substances
19 drugs (16 approved, 3 experimental)
- Myotoxicity
- Ototoxicity
15 drugs (10 approved, 5 experimental)
- Propofol Infusion Syndrome
1 drug approved
- Serotonin Syndrome
2 drugs approved
- Toxic Optic Neuropathy
3 drugs (2 approved, 1 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (229)
- ubiquinone
- hydrochlorothiazide
- bnt162b2
- amphotericin b
- ciprofloxacin
- norfloxacin
- prednisolone
- amifostine
- belatacept
- tenofovir alafenamide
- kang fu
- atorvastatin
- cefazolin
- empagliflozin
- lidocaine
- oprelvekin
- Filgrastim
- mrna-1273
- pregabalin
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- chlorpheniramine
- pioglitazone
- nefopam
- paritaprevir
- tenofovir
- granisetron
- basiliximab
- cyclophosphamide
- lamivudine
- allisartan isoproxil
- +199 more
Phase 3 trials (144)
- loratadine
- diosmetine
- palifermin
- pyridoxine
- yiqi-wenjing
- goserelin
- trastuzumab
- vinorelbine
- qls12010
- sodium picosulfate
- calmangafodipir
- gimeracil
- doxycycline
- nimotuzumab
- rozanolixizumab
- bevacizumab
- silymarin
- 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose
- itraconazole
- pegaspargase
- octreotide
- topotecan
- bisacodyl
- endostatin
- fosnetupitant
- asparaginase
- mercaptopurine
- omeprazole
- cytarabine
- olaparib
- +114 more
Phase 2 trials (196)
- trifluridine
- sirolimus
- lithium
- allogeneic hematopoietic stem cells
- son-080
- dantrolene
- acetazolamide
- floxuridine
- palmitoylethanolamide
- tryptophan
- bendamustine
- ferrous sulfate
- monosialoganglioside
- anti-psma designer t cells
- selinexor
- and017
- erlotinib
- miconazole
- clindamycin
- allogeneic bone marrow
- cd33 car-t cells
- yk-029a
- cobicistat
- apixaban
- acalabrutinib
- methadone
- interferon alpha-1
- allogeneic natural killer cells
- Cetalkonium
- denileukin diftitox
- +166 more
Phase 1 trials (81)
- caffeine
- ec-18
- flax
- scelectium tortuosum
- dimercaptopropane-1-sulfonate
- glycerol phenylbutyrate
- 19f cell sense-labeled pbmc
- ono-7746
- tetrahydrocannabinol
- betaxolol
- dobutamine
- digoxin
- creatine
- gfh312
- 188re-nm-02
- pneumococcal protein vaccine
- ipilimumab
- tumour infiltrating lymphocytes
- mw151
- gw003
- orange
- fingolimod
- allogeneic adipose derived mesenchymal stem cell
- motexafin gadolinium
- polymyxin b sulfate
- lometrexol
- trimethoprim
- cefepime
- 18f-ly3950321
- obi-833
- +51 more
Other trials (108)
- adapalene
- tetraprenylacetone
- pentoxifylline
- b multivitamins
- polyacrylate-16
- lactobacillus reuteri
- allogeneic blood cells
- rivastigmine
- finasteride
- hydroxyethyl starch
- cyanocobalamin
- human fecal microbiota
- tartaric acid
- acetyl zingerone
- mulberry leaf extract
- kuh-seng
- betaine
- lactobacillus salivarius
- strawberry
- ringer's lactate
- niacin
- lysine
- sh-ds01
- oligo fucoidan
- piperacillin
- dezocine
- carbon dioxide
- moringa
- bifidobacterium breve
- Efbemalenograstim alpha
- +78 more
Organizations
Organization Involved with Phase 4 Indications (33)
- McNeil
- Veloxis Pharmaceuticals
- Israel Defense Force
- Huazhong University of Science and Technology
- Augusta University
- Boston University
- Duke University
- Emory University
- National Cheng Kung University
- Oncologia Medica dell'Ospedale Fatebenefratelli
- Policlinique Médicale Universitaire
- Seoul National University
- University of Lausanne
- University of Oslo
- University of Saskatchewan
- Assiut University
- University of California, Davis
- University of Colorado, Denver
- Saskatoon Health Region
- I-Shou University
- National Taiwan University
- Louisiana State University
- Rush University
- Sun Yat-Sen University
- Mario Negri Institute
- Gundersen Health System
- University of Sao Paulo
- University of Colorado
- Sylvia Fedoruk Canadian Centre for Nuclear Innovation
- Government of Taiwan
- +3 more
Organization Involved with Phase 3 Indications (21)
- Pharmaceutical Project Solutions, Inc.
- Wellstat Therapeutics
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- Case Western Reserve University
- University of London
- Harvard University
- Temple University
- Gynecologic Oncology Group
- NRG Oncology
- Radiation Therapy Oncology Group
- Sichuan University
- University of South Florida
- Mayo Clinic
- Centre de Recherche Médicale de Lambaréné
- Zhejiang University
- Shandong University
- University of Texas at Houston
- University of Tuebingen
- Centre de Recherches Médicales de Lambaréné
- Barts & The London NHS Trust
Organization Involved with Phase 2 Indications (42)
- Ligand Pharmaceuticals
- Bristol-Myers Squibb
- Gilead Sciences
- Infan Industria Quimica Farmaceutica Nacional
- Eagle Pharmaceuticals, Inc.
- University of Arizona
- Anhui Medical University
- Chang Gung University
- Grupo Espanol de Investigacion en Sarcomas
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Guangzhou Medical University
- Herbert Irving Comprehensive Cancer Center
- Katholieke Universiteit Leuven
- Oregon Health and Science University
- Saint-Joseph University
- Southern China Urology Cancer Consortium
- Stanford University
- Thammasat University
- Thomas Jefferson University
- University of Florida
- University of Milan
- University of Tennessee
- University of Birmingham
- Wake Forest University
- Peking University
- Tel Aviv University
- University of California, Los Angeles
- University of California, San Francisco
- University of Chicago
- University of Utah
- +12 more
Organization Involved with Phase 1 Indications (22)
- Horizon Pharma
- AstraZeneca
- GlaxoSmithKline
- Kwang Dong Pharmaceutical co., ltd.
- Population Council
- National Institute on Aging (NIA)
- Eastern Cooperative Oncology Group
- Indiana University
- New York University
- University of Kansas
- University of Kentucky
- University of Rochester
- University of Southern California
- Virginia Commonwealth University
- University of Cambridge
- University of Cincinnati
- QPS
- Pharmaceutical Research Associates, Inc. (PRA)
- University of North Carolina at Chapel Hill
- Lundbeck
- Yeshiva University
- ImmunoChem Therapeutics, LLC
Organization Involved with Other Experimental Indications (18)
- National Institute of General Medical Sciences (NIGMS)
- Aarhus University
- Johns Hopkins University
- Trakya University
- University Hospital Hradec Kralove
- Chinese University of Hong Kong
- University of Ulsan
- The University of Hong Kong
- Government of Korea
- Catholic University of Korea
- Charles University
- Sungkyunkwan University
- People's Liberation Army of China
- University of Picardie Jules Verne
- Seonam University
- Yuksek Ihtisas University
- Consorci Sanitari de l'Anoia
- Centre Clinical, France